stockrow
Thursday 12 November 2026
Export INCY’s income statement to Excel — free account
Incyte Corporation
INCYIncyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −277.9%
- Free cash flow
- −233.0%
- Total debt
- −10.5%
Quarter to September 2026, against a year earlier
121.89
0.38
−0.31%
Follow INCY
Alert me
Incyte Corporation (INCY) Operating cash flow
Incyte Corporation's operating cash flow for fiscal 2025 was $1.4B, up 321.5% from $335.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $745.0M. Over the past ten years it has ranged from −$124.6M (fiscal 2020) to $1.4B (fiscal 2025) — the current reading is the highest in ten years. Incyte Corporation ranks 11th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $1.4B | 321.52% |
| FY2024 | $335.3M | (32.46%) |
| FY2023 | $496.5M | (48.81%) |
| FY2022 | $969.9M | 29.41% |
| FY2021 | $749.5M | — |
| FY2020 | −$124.6M | — |
| FY2019 | $710.7M | 111.36% |
| FY2018 | $336.2M | — |
| FY2017 | −$93.0M | — |
| FY2016 | $304.8M | 240.86% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$675.3M | — |
| Jun 2026 | $507.7M | 37.45% |
| Mar 2026 | $369.4M | (32.02%) |
| Dec 2025 | $543.3M | (2.88%) |
| 43 more quarters | Free account |
Against its own ten years
Low −$124.6M
High $1.4B
Ten-year median
$336.2M
Current reading's percentile
100
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.7B |
| EXEL Exelixis, Inc. compare | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $955.9M |
| GMAB Genmab A/S Sponsored ADR compare | $875.0M |
| INCY Incyte Corporation | $745.0M |
| ASND Ascendis Pharma A/S compare | $404.1M |
| ROIV Roivant Sciences Ltd. compare | −$36.4M |
| BNTX BioNTech SE Sponsored ADR compare | −$277.2M |
| INSM Insmed, Inc. compare | −$595.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement